Awake Prone Positioning in Patients With COVID-19 Respiratory Failure: A Randomized Clinical Trial.

Summary

In 445 nonintubated adults with COVID-19 hypoxemic respiratory failure, offering ≥6 hours/day of awake prone positioning resulted in a 93.8% posterior probability of reducing intubation and/or death (mean OR 0.74). Secondary outcomes showed small, probabilistic improvements in days alive outside ICU and hospital.

Key Findings

• Primary composite (intubation/death by day 28): posterior probability of benefit with APP 93.8% (mean OR 0.74; 95% CrI 0.48–1.09).
• Secondary outcomes favored APP with probabilistic gains in days alive outside ICU (+1.28 days, 95% CrI −0.78 to 3.34) and outside hospital (+1.55 days, 95% CrI −0.22 to 3.32).
• Intervention target was ≥6 hours/day awake prone positioning; analysis was intention-to-treat with Bayesian modeling.

Clinical Implications

Offer daily awake prone positioning for at least 6 hours to nonintubated adults with hypoxemic COVID-19 pneumonia, with monitoring for tolerance and adherence; incorporate into respiratory support bundles.

Limitations

• Credible interval crossed 1.0; not blinded and standard care allowed spontaneous APP
• Adherence and actual prone duration variability may dilute effect estimates

Future Directions

Define optimal duration, timing, and patient selection for APP; evaluate synergistic protocols with HFNC/NIV and implementation strategies across healthcare systems.